NASDAQ:KZR

Kezar Life Sciences Competitors

$6.04
-0.14 (-2.27 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$5.99
Now: $6.04
$6.24
50-Day Range
$5.48
MA: $6.11
$6.80
52-Week Range
$4.00
Now: $6.04
$9.79
Volume104,468 shs
Average Volume285,122 shs
Market Capitalization$290.32 million
P/E RatioN/A
Dividend YieldN/A
Beta0.33

Competitors

Kezar Life Sciences (NASDAQ:KZR) Vs. YMAB, DVAX, PRAX, RPTX, OMER, and MRSN

Should you be buying KZR stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Kezar Life Sciences, including Y-mAbs Therapeutics (YMAB), Dynavax Technologies (DVAX), Praxis Precision Medicines (PRAX), Repare Therapeutics (RPTX), Omeros (OMER), and Mersana Therapeutics (MRSN).

Y-mAbs Therapeutics (NASDAQ:YMAB) and Kezar Life Sciences (NASDAQ:KZR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation and profitability.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Y-mAbs Therapeutics and Kezar Life Sciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Y-mAbs Therapeutics02602.75
Kezar Life Sciences01202.67

Y-mAbs Therapeutics presently has a consensus price target of $58.1429, indicating a potential upside of 120.41%. Kezar Life Sciences has a consensus price target of $15.00, indicating a potential upside of 148.34%. Given Kezar Life Sciences' higher possible upside, analysts clearly believe Kezar Life Sciences is more favorable than Y-mAbs Therapeutics.

Institutional and Insider Ownership

53.2% of Y-mAbs Therapeutics shares are held by institutional investors. Comparatively, 49.5% of Kezar Life Sciences shares are held by institutional investors. 38.4% of Y-mAbs Therapeutics shares are held by company insiders. Comparatively, 7.6% of Kezar Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Volatility and Risk

Y-mAbs Therapeutics has a beta of 1.36, meaning that its stock price is 36% more volatile than the S&P 500. Comparatively, Kezar Life Sciences has a beta of 0.33, meaning that its stock price is 67% less volatile than the S&P 500.

Profitability

This table compares Y-mAbs Therapeutics and Kezar Life Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Y-mAbs TherapeuticsN/A-74.98%-66.70%
Kezar Life SciencesN/A-31.71%-29.17%

Valuation and Earnings

This table compares Y-mAbs Therapeutics and Kezar Life Sciences' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Y-mAbs TherapeuticsN/AN/A$-81,030,000.00($2.30)-11.47
Kezar Life SciencesN/AN/A$-35,090,000.00($1.84)-3.28

Y-mAbs Therapeutics is trading at a lower price-to-earnings ratio than Kezar Life Sciences, indicating that it is currently the more affordable of the two stocks.

Summary

Kezar Life Sciences beats Y-mAbs Therapeutics on 6 of the 11 factors compared between the two stocks.

Dynavax Technologies (NASDAQ:DVAX) and Kezar Life Sciences (NASDAQ:KZR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability and risk.

Volatility and Risk

Dynavax Technologies has a beta of 1.34, indicating that its stock price is 34% more volatile than the S&P 500. Comparatively, Kezar Life Sciences has a beta of 0.33, indicating that its stock price is 67% less volatile than the S&P 500.

Earnings & Valuation

This table compares Dynavax Technologies and Kezar Life Sciences' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dynavax Technologies$35.22 million32.38$-152,600,000.00($1.87)-5.39
Kezar Life SciencesN/AN/A$-35,090,000.00($1.84)-3.28

Kezar Life Sciences has lower revenue, but higher earnings than Dynavax Technologies. Dynavax Technologies is trading at a lower price-to-earnings ratio than Kezar Life Sciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Dynavax Technologies and Kezar Life Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Dynavax Technologies-256.92%-193.85%-23.45%
Kezar Life SciencesN/A-31.71%-29.17%

Institutional and Insider Ownership

80.0% of Dynavax Technologies shares are owned by institutional investors. Comparatively, 49.5% of Kezar Life Sciences shares are owned by institutional investors. 13.3% of Dynavax Technologies shares are owned by insiders. Comparatively, 7.6% of Kezar Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and target prices for Dynavax Technologies and Kezar Life Sciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Dynavax Technologies00403.00
Kezar Life Sciences01202.67

Dynavax Technologies currently has a consensus price target of $16.3333, indicating a potential upside of 62.20%. Kezar Life Sciences has a consensus price target of $15.00, indicating a potential upside of 148.34%. Given Kezar Life Sciences' higher probable upside, analysts clearly believe Kezar Life Sciences is more favorable than Dynavax Technologies.

Summary

Dynavax Technologies beats Kezar Life Sciences on 7 of the 13 factors compared between the two stocks.

Praxis Precision Medicines (NASDAQ:PRAX) and Kezar Life Sciences (NASDAQ:KZR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, profitability and earnings.

Earnings & Valuation

This table compares Praxis Precision Medicines and Kezar Life Sciences' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Praxis Precision MedicinesN/AN/AN/AN/AN/A
Kezar Life SciencesN/AN/A$-35,090,000.00($1.84)-3.28

Analyst Recommendations

This is a summary of recent ratings and target prices for Praxis Precision Medicines and Kezar Life Sciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Praxis Precision Medicines00403.00
Kezar Life Sciences01202.67

Praxis Precision Medicines presently has a consensus target price of $60.3333, suggesting a potential upside of 104.24%. Kezar Life Sciences has a consensus target price of $15.00, suggesting a potential upside of 148.34%. Given Kezar Life Sciences' higher probable upside, analysts clearly believe Kezar Life Sciences is more favorable than Praxis Precision Medicines.

Insider & Institutional Ownership

49.5% of Kezar Life Sciences shares are held by institutional investors. 7.6% of Kezar Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Praxis Precision Medicines and Kezar Life Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Praxis Precision MedicinesN/AN/AN/A
Kezar Life SciencesN/A-31.71%-29.17%

Summary

Praxis Precision Medicines beats Kezar Life Sciences on 4 of the 7 factors compared between the two stocks.

Repare Therapeutics (NASDAQ:RPTX) and Kezar Life Sciences (NASDAQ:KZR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, institutional ownership and profitability.

Analyst Ratings

This is a summary of recent ratings for Repare Therapeutics and Kezar Life Sciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Repare Therapeutics01513.00
Kezar Life Sciences01202.67

Repare Therapeutics presently has a consensus price target of $39.40, indicating a potential upside of 28.01%. Kezar Life Sciences has a consensus price target of $15.00, indicating a potential upside of 148.34%. Given Kezar Life Sciences' higher possible upside, analysts clearly believe Kezar Life Sciences is more favorable than Repare Therapeutics.

Earnings and Valuation

This table compares Repare Therapeutics and Kezar Life Sciences' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Repare TherapeuticsN/AN/AN/AN/AN/A
Kezar Life SciencesN/AN/A$-35,090,000.00($1.84)-3.28

Insider & Institutional Ownership

64.8% of Repare Therapeutics shares are owned by institutional investors. Comparatively, 49.5% of Kezar Life Sciences shares are owned by institutional investors. 7.6% of Kezar Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Repare Therapeutics and Kezar Life Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Repare TherapeuticsN/AN/AN/A
Kezar Life SciencesN/A-31.71%-29.17%

Summary

Repare Therapeutics beats Kezar Life Sciences on 6 of the 8 factors compared between the two stocks.

Omeros (NASDAQ:OMER) and Kezar Life Sciences (NASDAQ:KZR) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation and analyst recommendations.

Earnings and Valuation

This table compares Omeros and Kezar Life Sciences' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Omeros$111.81 million10.10$-84,490,000.00($0.96)-18.99
Kezar Life SciencesN/AN/A$-35,090,000.00($1.84)-3.28

Kezar Life Sciences has lower revenue, but higher earnings than Omeros. Omeros is trading at a lower price-to-earnings ratio than Kezar Life Sciences, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

56.6% of Omeros shares are owned by institutional investors. Comparatively, 49.5% of Kezar Life Sciences shares are owned by institutional investors. 11.3% of Omeros shares are owned by insiders. Comparatively, 7.6% of Kezar Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Omeros and Kezar Life Sciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Omeros02402.67
Kezar Life Sciences01202.67

Omeros presently has a consensus target price of $23.40, indicating a potential upside of 28.36%. Kezar Life Sciences has a consensus target price of $15.00, indicating a potential upside of 148.34%. Given Kezar Life Sciences' higher probable upside, analysts clearly believe Kezar Life Sciences is more favorable than Omeros.

Profitability

This table compares Omeros and Kezar Life Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Omeros-134.59%N/A-59.49%
Kezar Life SciencesN/A-31.71%-29.17%

Volatility and Risk

Omeros has a beta of 1.65, indicating that its share price is 65% more volatile than the S&P 500. Comparatively, Kezar Life Sciences has a beta of 0.33, indicating that its share price is 67% less volatile than the S&P 500.

Summary

Omeros beats Kezar Life Sciences on 7 of the 12 factors compared between the two stocks.

Kezar Life Sciences (NASDAQ:KZR) and Mersana Therapeutics (NASDAQ:MRSN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, profitability and analyst recommendations.

Valuation and Earnings

This table compares Kezar Life Sciences and Mersana Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kezar Life SciencesN/AN/A$-35,090,000.00($1.84)-3.28
Mersana Therapeutics$42.12 million25.92$-28,210,000.00($0.65)-24.32

Mersana Therapeutics has higher revenue and earnings than Kezar Life Sciences. Mersana Therapeutics is trading at a lower price-to-earnings ratio than Kezar Life Sciences, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Kezar Life Sciences has a beta of 0.33, meaning that its stock price is 67% less volatile than the S&P 500. Comparatively, Mersana Therapeutics has a beta of 2.54, meaning that its stock price is 154% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Kezar Life Sciences and Mersana Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Kezar Life Sciences01202.67
Mersana Therapeutics02502.71

Kezar Life Sciences currently has a consensus target price of $15.00, suggesting a potential upside of 148.34%. Mersana Therapeutics has a consensus target price of $26.1667, suggesting a potential upside of 65.51%. Given Kezar Life Sciences' higher probable upside, equities analysts clearly believe Kezar Life Sciences is more favorable than Mersana Therapeutics.

Profitability

This table compares Kezar Life Sciences and Mersana Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Kezar Life SciencesN/A-31.71%-29.17%
Mersana Therapeutics-8,772.91%-45.16%-37.53%

Institutional & Insider Ownership

49.5% of Kezar Life Sciences shares are held by institutional investors. 7.6% of Kezar Life Sciences shares are held by insiders. Comparatively, 5.3% of Mersana Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Kezar Life Sciences beats Mersana Therapeutics on 7 of the 13 factors compared between the two stocks.


Kezar Life Sciences Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Y-mAbs Therapeutics logo
YMAB
Y-mAbs Therapeutics
1.6$26.38-8.0%$1.15 billionN/A-8.88News Coverage
Gap Down
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$10.07-1.0%$1.14 billion$35.22 million-7.35
Praxis Precision Medicines logo
PRAX
Praxis Precision Medicines
1.7$29.54-1.6%$1.14 billionN/A0.00Unusual Options Activity
Lockup Expiration
Repare Therapeutics logo
RPTX
Repare Therapeutics
1.8$30.78-0.7%$1.14 billionN/A0.00News Coverage
Omeros logo
OMER
Omeros
1.4$18.23-2.9%$1.13 billion$111.81 million-7.66Insider Selling
News Coverage
Gap Up
Mersana Therapeutics logo
MRSN
Mersana Therapeutics
1.5$15.81-1.8%$1.09 billion$42.12 million-11.71News Coverage
Gap Down
Constellation Pharmaceuticals logo
CNST
Constellation Pharmaceuticals
1.2$22.50-1.4%$1.08 billionN/A-8.30Analyst Report
News Coverage
Zogenix logo
ZGNX
Zogenix
1.7$19.27-0.9%$1.07 billion$3.65 million-2.03Analyst Upgrade
News Coverage
Trillium Therapeutics logo
TRIL
Trillium Therapeutics
1.7$10.42-7.3%$1.07 billion$120,000.00-3.86News Coverage
Gap Down
G1 Therapeutics logo
GTHX
G1 Therapeutics
1.5$25.57-1.3%$1.07 billionN/A-8.82
Syndax Pharmaceuticals logo
SNDX
Syndax Pharmaceuticals
1.6$22.16-2.8%$1.07 billion$1.52 million-11.79News Coverage
Gap Down
Rhythm Pharmaceuticals logo
RYTM
Rhythm Pharmaceuticals
1.8$21.27-1.9%$1.07 billionN/A-7.00
NKTX
Nkarta
1.8$32.28-1.6%$1.06 billionN/A0.00
MannKind logo
MNKD
MannKind
1.4$4.24-1.9%$1.05 billion$63.04 million-20.19News Coverage
Phibro Animal Health logo
PAHC
Phibro Animal Health
1.8$24.54-0.1%$992.72 million$800.40 million23.15News Coverage
Enanta Pharmaceuticals logo
ENTA
Enanta Pharmaceuticals
1.4$48.75-1.1%$983.39 million$122.47 million-26.79News Coverage
Arcturus Therapeutics logo
ARCT
Arcturus Therapeutics
1.6$37.00-1.8%$972.36 million$20.79 million-12.76
Akero Therapeutics logo
AKRO
Akero Therapeutics
1.7$27.76-1.9%$965.22 millionN/A-12.79
ESSA Pharma logo
EPIX
ESSA Pharma
1.4$28.37-0.2%$958.34 millionN/A-26.27
Annexon logo
ANNX
Annexon
1.9$24.93-0.9%$951.28 millionN/A0.00
Humanigen logo
HGEN
Humanigen
1.6$17.25-1.9%$922.56 millionN/A0.00
Radius Health logo
RDUS
Radius Health
1.3$19.49-2.0%$913.96 million$173.32 million-7.99News Coverage
Prothena logo
PRTA
Prothena
2.3$22.78-3.1%$911.34 million$810,000.00-8.90Gap Down
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.5$16.25-2.2%$891.85 million$227.19 million45.14Analyst Upgrade
Gap Down
BioXcel Therapeutics logo
BTAI
BioXcel Therapeutics
1.6$35.87-0.4%$881.43 millionN/A-10.64Analyst Report
Gap Down
Merus logo
MRUS
Merus
1.6$23.06-1.0%$879.21 million$31.13 million-7.51Analyst Report
Analyst Revision
Dyne Therapeutics logo
DYN
Dyne Therapeutics
1.6$16.75-0.0%$861.92 millionN/A0.00
Affimed logo
AFMD
Affimed
1.6$9.74-19.0%$860.30 million$23.96 million-16.51Unusual Options Activity
Analyst Revision
News Coverage
Gap Down
Epizyme logo
EPZM
Epizyme
1.8$8.37-0.6%$851.94 million$23.80 million-3.75
Amphastar Pharmaceuticals logo
AMPH
Amphastar Pharmaceuticals
1.5$17.89-0.6%$848.58 million$322.36 million127.79
Collegium Pharmaceutical logo
COLL
Collegium Pharmaceutical
1.4$23.33-1.3%$810.86 million$296.70 million47.61
ORIC Pharmaceuticals logo
ORIC
ORIC Pharmaceuticals
1.7$21.57-7.5%$791.51 millionN/A0.00Gap Down
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.6$5.37-1.1%$775.18 million$322.07 million-5.11
Esperion Therapeutics logo
ESPR
Esperion Therapeutics
1.4$26.95-4.7%$753.06 million$148.36 million-7.00Gap Down
Karyopharm Therapeutics logo
KPTI
Karyopharm Therapeutics
1.7$10.02-1.2%$747.83 million$40.89 million-3.46
Veru logo
VERU
Veru
1.4$10.35-0.3%$744.29 million$42.59 million-36.96
Ardelyx logo
ARDX
Ardelyx
1.6$7.44-5.6%$734.18 million$5.28 million-7.37Gap Down
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
2.2$22.17-5.3%$731.97 million$252 million-2.27Gap Down
Chimerix logo
CMRX
Chimerix
1.3$8.45-2.1%$723.99 million$12.52 million-14.82News Coverage
VBI Vaccines logo
VBIV
VBI Vaccines
1.5$2.82-1.8%$716.29 million$2.22 million-16.59
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$3.32-2.1%$714.48 million$150,000.00-4.74Gap Down
OrganiGram logo
OGI
OrganiGram
1.6$3.05-3.3%$708.43 million$64.61 million-4.49Upcoming Earnings
Analyst Upgrade
Gap Down
Calliditas Therapeutics AB (publ) logo
CALT
Calliditas Therapeutics AB (publ)
1.4$27.50-0.0%$686.58 million$19.56 million-19.78High Trading Volume
Gossamer Bio logo
GOSS
Gossamer Bio
1.7$8.74-3.3%$660.12 millionN/A-2.46Gap Down
Bicycle Therapeutics logo
BCYC
Bicycle Therapeutics
1.3$28.38-13.7%$655.29 million$13.80 million-13.71Insider Selling
Gap Down
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$6.23-5.6%$651.22 million$143.01 million-1.19Gap Down
IDEAYA Biosciences logo
IDYA
IDEAYA Biosciences
1.5$19.86-9.5%$640.68 millionN/A-10.56Gap Down
KalVista Pharmaceuticals logo
KALV
KalVista Pharmaceuticals
1.8$26.15-0.1%$635.65 million$12.69 million-12.57
Xenon Pharmaceuticals logo
XENE
Xenon Pharmaceuticals
1.6$17.62-1.3%$630.96 million$6.83 million-18.16News Coverage
Kadmon logo
KDMN
Kadmon
1.8$3.66-5.2%$628.85 million$5.09 million-6.10Analyst Upgrade
Gap Down
This page was last updated on 4/10/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.